These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1622 related items for PubMed ID: 15621213

  • 1. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
    Youdim MB, Fridkin M, Zheng H.
    Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
    [Abstract] [Full Text] [Related]

  • 2. A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease.
    Weinstock M, Gorodetsky E, Poltyrev T, Gross A, Sagi Y, Youdim M.
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Jun; 27(4):555-61. PubMed ID: 12787840
    [Abstract] [Full Text] [Related]

  • 3. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition.
    Youdim MB, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, Amit T.
    J Neurosci Res; 2003 Jun; 79(1-2):172-9. PubMed ID: 15573406
    [Abstract] [Full Text] [Related]

  • 4. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30.
    Youdim MB.
    Curr Alzheimer Res; 2006 Dec; 3(5):541-50. PubMed ID: 17168653
    [Abstract] [Full Text] [Related]

  • 5. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives.
    Mandel S, Weinreb O, Amit T, Youdim MB.
    Brain Res Brain Res Rev; 2005 Apr; 48(2):379-87. PubMed ID: 15850677
    [Abstract] [Full Text] [Related]

  • 6. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S, Zheng H, Fridkin M, Youdim MB.
    J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
    [Abstract] [Full Text] [Related]

  • 7. Multi target neuroprotective and neurorestorative anti-Parkinson and anti-Alzheimer drugs ladostigil and m30 derived from rasagiline.
    Youdim MB.
    Exp Neurobiol; 2013 Mar; 22(1):1-10. PubMed ID: 23585716
    [Abstract] [Full Text] [Related]

  • 8. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
    Youdim MB, Fridkin M, Zheng H.
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
    [Abstract] [Full Text] [Related]

  • 9. Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil.
    Youdim MB, Amit T, Bar-Am O, Weinreb O, Yogev-Falach M.
    Neurotox Res; 2006 Dec; 10(3-4):181-92. PubMed ID: 17197368
    [Abstract] [Full Text] [Related]

  • 10. Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease.
    Avramovich-Tirosh Y, Amit T, Bar-Am O, Zheng H, Fridkin M, Youdim MB.
    J Neurochem; 2007 Jan; 100(2):490-502. PubMed ID: 17144902
    [Abstract] [Full Text] [Related]

  • 11. A multifunctional, neuroprotective drug, ladostigil (TV3326), regulates holo-APP translation and processing.
    Yogev-Falach M, Bar-Am O, Amit T, Weinreb O, Youdim MB.
    FASEB J; 2006 Oct; 20(12):2177-9. PubMed ID: 16935943
    [Abstract] [Full Text] [Related]

  • 12. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
    Zheng H, Gal S, Weiner LM, Bar-Am O, Warshawsky A, Fridkin M, Youdim MB.
    J Neurochem; 2005 Oct; 95(1):68-78. PubMed ID: 16181413
    [Abstract] [Full Text] [Related]

  • 13. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR.
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [Abstract] [Full Text] [Related]

  • 14. Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: involvement of MAPK and PKC activation.
    Bar-Am O, Amit T, Weinreb O, Youdim MB, Mandel S.
    J Alzheimers Dis; 2010 Dec; 21(2):361-71. PubMed ID: 20555137
    [Abstract] [Full Text] [Related]

  • 15. Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease.
    Youdim MB, Kupershmidt L, Amit T, Weinreb O.
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S132-6. PubMed ID: 24262165
    [Abstract] [Full Text] [Related]

  • 16. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].
    Youdim MB, Weinstock M.
    Cell Mol Neurobiol; 2001 Dec; 21(6):555-73. PubMed ID: 12043833
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
    Youdim MB, Weinstock M.
    Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
    [Abstract] [Full Text] [Related]

  • 18. From anti-Parkinson's drug rasagiline to novel multitarget iron chelators with acetylcholinesterase and monoamine oxidase inhibitory and neuroprotective properties for Alzheimer's disease.
    Zheng H, Amit T, Bar-Am O, Fridkin M, Youdim MB, Mandel SA.
    J Alzheimers Dis; 2012 Jan; 30(1):1-16. PubMed ID: 22387411
    [Abstract] [Full Text] [Related]

  • 19. Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease?
    Tabakman R, Lecht S, Lazarovici P.
    Bioessays; 2004 Jan; 26(1):80-90. PubMed ID: 14696044
    [Abstract] [Full Text] [Related]

  • 20. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ, Swope DM, Dashtipour K.
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 82.